Nav: Home

CNIO researchers discover a mechanism that reverses resistance to antiangiogenic drugs

June 09, 2016

Researchers from the Breast Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) have just published an important finding regarding antiangiogenic drugs, one of the most commonly used drugs to treat cancer. In a paper published in Cell Reports they describe a resistance mechanism to these compounds and, more importantly, a way to reverse it. Working on mice with breast and lung cancer, they noted that when they added an antidiabetic agent to the antiangiogenic drug regimen, tumour growth was inhibited by 92%.

Resistance to antiangiogenic agents is a common problem in epithelial tumours and this is particularly relevant if one takes into account that these agents are widely-used in cancer treatment; they are used to combat breast cancer, lung cancer, colorectal cancer, ovarian cancer, kidney cancer and liver carcinomas, among others.

Tyrosine Kinase Inhibitors (TKIs) belong to the family of antiangiogenic drugs. Nintedanib -a new TKI that to date provides better results than sorafenib and sunitinib- has just been approved by the FDA and EMEA for the treatment of advanced lung cancer. Therefore, according to the authors of this paper, "it is important to define the acquired resistance mechanisms to TKIs," in order to prolong the time that patients can benefit from these treatments.

CHANGES IN CELL METABOLISM

Abnormal blood vessels support tumour development and cause a decrease in oxygen (hypoxia) in these tissues. The lack of oxygen triggers changes in cell metabolism; a phenomenon known as the Warburg effect. Cancer cells consume up to 20 times more glucose than normal cells, thus overriding the cells' standard power houses: the mitochondria.

Treatment with TKIs prevents the uncontrolled glucose metabolism of cancer cells, according to the observations of Miguel Quintela-Fandino, head of the Breast Cancer Clinical Research Unit at the CNIO, and of his team. This treatment, however, which should result in cancer cells dying from starvation, does not always have the desired lethal effect and many tumours acquire resistance. How does this occur? As explained in this paper: by changing the energy source and reverting to mitochondrial respiration.

However, CNIO researchers have discovered that this adaptive mechanism that tumours use to survive also provides an opportunity to attack those cancer cells.

AN ANTIDIABETIC AGENT TO COMBAT CANCER

"When one energy source (glycolysis) is limited pharmacologically, tumours become vulnerable to the inhibition of another energy source (mitochondrial metabolism)", the authors point out in the pages of Cell Reports. So, they tested this hypothesis in mice with breast cancer that were being treated with the TKI nintedanib, and they found that glucose consumption severely dropped in the cancer cells while there was an enrichment of metabolites that result from mitochondrial respiration.

Then, they added a mitochondrial blocker (the antidiabetic phenformin) to the drug regimen and saw how up to 92 % of the tumour growth was inhibited in these mice; especially when phenformin was administered sequentially -instead of simultaneously- to the animals taking the TKIs.

This effect, which they named "metabolic synthetic lethality," also occurred using drug combinations of other types of TKIs (regorafenib) with mitochondrial inhibitors (ME344). It was also noted that in lung cancer models, this treatment prolonged median overall survival by >40%.

The most interesting aspect about this project is that it can be applied immediately. "Phenformin was withdrawn from the market due to a rare complication caused in diabetic patients. However, the drug is safe in non-diabetic patients", says Quintela. His group will launch an independent clinical trial within the next six months in which "patients will receive this synergistic combination to study the reversion of resistance to antiangiogenic drugs."
-end-
This research project has been funded by the Spanish Ministry of Health, the Spanish Association against Cancer, the Rosae Foundation, Avon Spain and "La Caixa" Foundation.

Centro Nacional de Investigaciones Oncológicas (CNIO)

Related Breast Cancer Articles:

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
More Breast Cancer News and Breast Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.